The U.S. Food and Drug Administration (FDA) has cleared Medtronic’s In.Pact Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) for the superficial femoral and popliteal arteries in the upper leg. This is the second drug-eluting balloon (DEB) cleared by the FDA, the first being C. R. Bard’s Lutonix 035 approved in November. 
 

New data from the Boston Scientific clinical trial program of the Lotus Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement.

Patients who were obese before developing heart failure lived longer than normal weight patients with the same condition according to a new study in the Journal of the American College of Cardiology that examined the “obesity paradox” by following obese and non-obese heart failure patients for more than a decade.

bioresorbable stents

Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the coming years if the data trend continues. New data from TCT 2014 further reinforces this.

Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. 

Roxwood Medical Inc. announced U.S. Food and Drug Administration (FDA) clearance for the U.S. commercialization of its CenterCross Catheter for use in the coronary and peripheral vasculature.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now